Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    134
    ...
ATC Name B/G Ingredients Dosage Form Price
L02BG04 FEMAZOL G Letrozole - 2.5mg 2.5mg Tablet, film coated 1,433,432 L.L
N01AX10 DORMIFOR G Propofol - 1% 1% Injectable emulsion 1,081,473 L.L
N03AG01 VILAPRO CHRONO 500 G Sodium valproate - 333mg, Valproic acid - 145mg Tablet, film coated, prolonged release 217,702 L.L
P01AB01 PHOSVIT G Metronidazole benzoate - 125mg/5ml 125mg/5ml Suspension 207,336 L.L
R05CB06 MUCOXELLIN LA G Ambroxol - 75mg 75mg Capsule 276,448 L.L
S02CA05 CETRAXAL PLUS G Ciprofloxacine HCl monohydrate - 3mg/ml, Fluocinolone acetonide - 0.25mg/ml Drops solution 795,555 L.L
A02BX02 SUCRATE GEL G Sucralfate - 1g 1g Gel 636,981 L.L
A11CC06 DEDROGYL G Calcifediol - 15mg/100ml 15mg/100ml Drops solution 827,807 L.L
B03BA01 COBAL G Vitamin B12 - 500mcg 500mcg Tablet, coated 486,471 L.L
B05XA01 CHLORURE DE POTASSIUM PROAMP G Potassium chloride - 0.0746g/ml 0.0746g/ml Injectable concentrated solution 1,444,631 L.L
C09CA07 TELMICARD 80 G Telmisartan - 80mg 80mg Tablet 865,179 L.L
D10BA01 CURACNE G Isotretinoin - 10mg 10mg Capsule, soft gelatin 970,254 L.L
J01DB05 ROXIL G Cefadroxil (monohydrate) - 250mg/5ml 250mg/5ml Powder for suspension 459,594 L.L
J01MA02 VONECIP G Ciprofloxacin - 200mg/100ml 200mg/100ml Injectable solution 579,196 L.L
L01EB02 TARESSA 150 G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 98,617,813 L.L
L02BG04 LEFFTARA G Letrozole - 2.5mg 2.5mg Tablet, film coated 2,060,111 L.L
M01AB05 DILO G Diclofenac potassium - 50mg 50mg Tablet 223,974 L.L
N01AX10 PROPOFOL 1% MCT/LCT FRESENIUS G Propofol - 1% 1% Injectable emulsion 847,965 L.L
N03AG01 CONVULEX G Sodium valproate - 100mg/ml 100mg/ml Injectable solution 4,441,399 L.L
P01AB01 PHOZOLE G Metronidazole benzoate - 125mg/5ml 125mg/5ml Suspension 207,336 L.L
R05CB06 SOLVAMUC SR G Ambroxol - 75mg 75mg Capsule 276,448 L.L
S02CA06 POLYDEXA G Dexamethasone sodium metasulfobenzoate - 1.000.000IU/100ml, Polymyxin B sulfate - 100mg/100ml, Neomycin sulfate - 650.000IU/100ml Drops solution 208,296 L.L
V03AE02 SEVELAMER CARBONATE ARROW G Sevelamer carbonate - 800mg 800mg Tablet, film coated L.L
B03BA01 CYNOVIT-JULPHAR G Vitamin B12 - 1mg/ml 1mg/ml Injectable solution 167,980 L.L
B05XA01 CHLORURE DE POTASSIUM RENAUDIN G Potassium chloride - 7.46g/100ml 7.46% Injectable solution 385,683 L.L
C05CA03 DIOSMINE BIOGARAN CONSEIL G Diosmin - 600mg 600mg Tablet, coated 761,959 L.L
C09CA07 TOLURA G Telmisartan - 80mg 80mg Tablet 698,798 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 5mg 5mg Tablet, film coated 360,918 L.L
D10BA01 CURACNE G Isotretinoin - 10mg 10mg Capsule, soft gelatin 970,254 L.L
J01DB05 BIODROXIL G Cefadroxil (monohydrate) - 1000mg 1,000mg Tablet, film coated 1,091,442 L.L
    ...
    134
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026